A new way to diagnose narcolepsy using T cells could help Jazz Pharmaceuticals find patients eligible to take Xyrem. In addition, GlaxoSmithKline wants to use the findings to develop influenza vaccines that lack the extremely rare side effect of inducing narcolepsy.